KOSDAQFood & Beverage218150

Milae Bioresources

₩1,529▼ 1.35%2026-11-18 close
Market Cap
₩31.2B
Turnover
₩36,083,198
Volume
20K
Shares out.
20.4M
PER
—
PBR
0.8×
EPS
-₩157
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Quarterly Profit Recovery After the 2025 Losses

Milae Bioresources, centered on feed additives and pet health supplements, recorded an operating loss and a net loss attributable to controlling shareholders in 2025, while operating profit has increased for two consecutive quarters since turning positive in the first quarter of 2026.

  1. 1

    The 2025 operating loss was KRW 1.44 billion and the net loss attributable to controlling shareholders was KRW 3.26 billion, marking two consecutive loss years from 2024 to 2025.

  2. 2

    Q3 2026 operating profit of KRW 796 million fell 35.7% from a year earlier, while net profit attributable to controlling shareholders of KRW 1.49 billion turned positive and rose 33.4% year on year. Operating profit and net profit moved in opposite directions that quarter.

  3. 3

    Most revenue comes from the feed segment, with the food segment accounting for the rest. Saramin company data shows a business mix of 75.4% feed and 23.9% food.

  4. 4

    Over the last four quarters, the net loss attributable to controlling shareholders totals KRW 3.08 billion, so PER is not calculated, while the price-to-book ratio remains below 1 times.

  5. 5

    The representative director changed to Lee Jae-hwan in March 2026, and an official distributor agreement for feed enzyme solutions was signed in December 2025.

02

Business structure

Milae Bioresources was founded in 1998 and started with livestock feed additive manufacturing before expanding into pet health supplements and food ingredients. The business is split into a feed segment and a food segment.

Saramin company data puts the business mix at 75.4% feed and 23.9% food, while a April 2022 report from Asia Economy said the feed segment accounted for more than 80% of revenue at the end of 2021. The two data points come from different dates, so it is difficult to determine how the mix has shifted in between.

The core of the feed segment is specialty processed raw materials (EP) made from corn, soybean and oat, along with premix feed additives.

The premix additive ML-F1, launched in 2014, is a GABA-containing stress reliever, and its export version ML-F2 has been shipped to markets including the Philippines, Bangladesh and Taiwan according to the company history.

The pet segment consists of the company's own brand Optipet along with ODM supply of health supplements for third-party brands such as Coupang's pet brand and Cargill Agri Purina's daycare product. The food segment handles edible eggs and functional ingredients.

In October 2024 the company brought the beverage maker Geonganmaeul in as a subsidiary, adding a beverage business. In July 2025 its Icheon No. 2 plant was registered as a US FDA-compliant production facility, and in September 2025 an eye-health raw material received individual functional recognition.

Customers include domestic feed manufacturers and pet product distribution channels. The company is classified as a small and mid-sized enterprise that competes on proprietary raw material technology.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩18.7B₩1.2B6.6%
2025Q4₩17.4B-₩3.3B−19.2%
2026Q1₩17B₩400M2.6%
2026Q2₩19.3B₩700M3.6%
2026Q3₩20.8B₩800M3.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩75.6B₩1.6B₩1B2.1%2.4%37.4%
2023₩60B₩20,185,933₩400M0.0%1.0%16.8%
2024₩62.5B₩200M-₩400M0.3%−1.0%39.9%
2025₩67.6B-₩1.4B-₩3.3B−2.1%−8.1%37.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

On a disclosed annual basis, revenue fell from KRW 75.6 billion in 2022 to KRW 60 billion in 2023, a 20.7% decline, then rose to KRW 62.5 billion in 2024 (up 4.1%) and KRW 67.6 billion in 2025 (up 8.2%).

Revenue has increased for two consecutive years from 2024 to 2025, with 2022 the largest year and 2023 the smallest in the 2022–2025 period. Operating profit dropped from KRW 1.58 billion in 2022 to KRW 20.19 million in 2023, a 98.7% decline.

It recovered to KRW 184 million in 2024, up 810.2%, before the company posted an operating loss of KRW 1.44 billion in 2025, a swing into the red. The operating margin moved from 2.1% in 2022 to 0.0% in 2023, 0.3% in 2024 and -2.1% in 2025, so the margin did not improve even as revenue grew in 2024 and 2025.

Net profit attributable to controlling shareholders was KRW 963 million in 2022 and KRW 441 million in 2023, a 54.2% decline, then turned to a loss of KRW 433 million in 2024 and widened to a loss of KRW 3.26 billion in 2025, which the filings describe as continued losses with an expanded deficit.

Net income including non-controlling interests was a loss of KRW 2.99 billion in 2025, which differs from the controlling-shareholder figure because of the non-controlling interest share.

On a quarterly basis, operating profit of KRW 1.24 billion in Q3 2025 turned into an operating loss of KRW 3.34 billion in Q4 2025, when the net loss attributable to controlling shareholders reached KRW 5 billion. FnGuide financial data show that selling expenses rose sharply in 2025 compared with the prior year.

Q1 2026 operating profit of KRW 439 million marked a swing to profit, followed by KRW 698 million in Q2 (up 59.1% from the prior quarter) and KRW 796 million in Q3 (up 14.1%), an increase for two consecutive quarters.

Q3 2026 revenue of KRW 20.8 billion rose 11.1% year on year, yet operating profit fell 35.7% over the same period, so higher sales did not translate into higher profit.

Net profit attributable to controlling shareholders swung to a loss of KRW 65.77 million in Q2 2026 and back to a profit of KRW 1.49 billion in Q3 2026, showing large quarter-to-quarter swings. The net loss attributable to controlling shareholders over the last four quarters totals KRW 3.08 billion. Operating cash flow turned from -KRW 966 million in 2024 to KRW 4.4 billion in 2025.

05

Industry analysis

The feed industry depends heavily on imported raw materials, so profitability is sensitive to exchange rates and input prices. The company's 2023 business report noted that most feed raw materials are imported and that prices rose sharply during a period of high exchange rates and inflation.

That environment raised demand for feed additives that lower feed costs and improve feed efficiency, and the company said it sourced and introduced such additives in Korea.

For the first half of 2026, FnGuide-linked company monitor commentary attributed the improvement to rising demand for eco-friendly and functional products, including higher-value additives such as probiotics and enzymes. Overseas exports and ODM/OEM production for Optipet were also cited.

The food segment's pricing moves with farm-gate egg prices; a 2022 press report said higher farm-gate egg prices lifted food segment sales. Pet food is named by the company as a growth driver, and it operates a dedicated pet food plant that received HACCP certification.

On competition, the company differentiates through proprietary specialty raw materials, a GABA-based additive and pet supplement ODM capabilities. Data comparing its market share or scale with key rivals in feed additives were not available for this analysis.

Reading the company's disclosed results alongside raw material and exchange-rate trends is the most direct way to place it in its industry context.

06

Outlook

The company has disclosed several business milestones. In July 2025 its Icheon No. 2 plant was registered as a US FDA-compliant production facility, and in September 2025 an eye-health raw material received individual functional recognition.

In December 2025 an official distributor agreement for feed enzyme solutions was signed with IFF Danisco. In March 2026 the representative director changed to Lee Jae-hwan. FnGuide-linked company monitor commentary cited Optipet's overseas exports and higher ODM/OEM production as drivers of first-half 2026 results.

In food, the company's recruitment information page describes planned development of products such as hangover relief, sarcopenia-related and low-fat protein supplements, but no launch schedule or revenue contribution has been disclosed.

The company has leaned into specialty processed raw materials and functional additives in its feed segment, and that focus coincided with higher Q3 2026 revenue. Operating profit in Q3 2026 nevertheless declined from a year earlier, so whether sales growth turns into margin recovery is the central question.

Whether the swing from a Q2 2026 net loss to a Q3 2026 net profit reflects a lasting change cannot be judged from quarterly data alone. The next checkpoint is how the 2026 annual business report presents the full-year operating margin and the net profit attributable to controlling shareholders.

07

Valuation

PER
—
PBR
0.8×
ROE
-7.1%
EPS
-₩157
BPS
₩2,141
Dividend per share
₩0

Because the net loss attributable to controlling shareholders over the last four quarters totals KRW 3.08 billion, PER is not calculated, so earnings-based multiples cannot be used to compare the current share price. The price-to-book ratio, by contrast, remains below 1 times, meaning the stock trades below book value.

At the end of 2025, total equity was KRW 42.8 billion, of which KRW 40.4 billion belonged to controlling shareholders, and market capitalization sits below the controlling-shareholder equity. Dividend levels are not significant, so shareholder returns through dividends are difficult to identify at present.

On the balance sheet, the debt ratio rose from 16.8% in 2023 to 39.9% in 2024 and eased to 37.9% in 2025, with total liabilities of KRW 16.2 billion at the end of 2025.

On earnings, controlling-shareholder net profit returned to positive in Q3 2026, but the last four quarters still total a net loss, so an earnings multiple does not yet apply. A factual reading of valuation therefore depends on whether the earnings recovery holds, viewed alongside the asset base.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Quarterly profit has turned

Operating profit turned positive in Q1 2026 and increased for two consecutive quarters through Q3. Net profit attributable to controlling shareholders of KRW 1.49 billion in Q3 2026 returned to profit and rose 33.4% year on year. The recovery follows an operating loss of KRW 3.34 billion in Q4 2025.

Partnerships and certifications expanding

In July 2025 the Icheon No. 2 plant was registered as a US FDA-compliant production facility. An official distributor agreement for feed enzyme solutions was signed in December 2025, and an eye-health raw material received individual functional recognition in September 2025.

Company monitor commentary said Optipet's overseas exports and ODM/OEM production contributed to first-half 2026 results.

Balance sheet capacity

Total equity at the end of 2025 was KRW 42.8 billion, with KRW 40.4 billion attributable to controlling shareholders. Total liabilities were KRW 16.2 billion, and the debt ratio eased to 37.9% from 39.9% in 2024. Operating cash flow swung from -KRW 966 million in 2024 to KRW 4.4 billion in 2025.

09

Bear factors

Annual losses continue

The company swung to an operating loss of KRW 1.44 billion in 2025, and the net loss attributable to controlling shareholders widened to KRW 3.26 billion. Losses have occurred in two consecutive years from 2024 to 2025. The operating margin fell to -2.1% in 2025 from 2.1% in 2022.

Large swings in quarterly results

In Q4 2025 the company posted an operating loss of KRW 3.34 billion and a net loss attributable to controlling shareholders of KRW 5 billion. In Q2 2026 it swung back to a net loss of KRW 65.77 million.

Cost and cash flow pressures

Q3 2026 operating profit fell 35.7% year on year even though revenue grew 11.1%, so higher sales did not carry through to profit. FnGuide data show selling expenses rose sharply in 2025.

10

Risk factors

Raw material prices and FX

The company's 2023 business report says most feed raw materials are imported. Raw material prices rose sharply during a period of high exchange rates and inflation, so the cost structure is exposed to FX and global input prices. Higher costs could push the operating margin lower again.

Concentration of the business

Most revenue comes from the feed segment, which makes the company sensitive to changes in the feed market. The food segment's pricing follows farm-gate egg prices, adding price volatility.

The revenue contribution of new businesses such as pet health supplements and food ingredients is difficult to separate in the disclosed figures.

Financial headroom and cash flow

Total liabilities rose from KRW 16.2 billion at the end of 2025 to KRW 17.7 billion at the end of March 2026 according to FnGuide. Operating cash flow was negative in Q1 2026. The equity base remains sizable, but financial headroom could narrow if the earnings recovery does not hold.

11

What to watch next

  1. By March 31, 2027

    This is the deadline for the 2026 annual business report. The full-year operating margin and net profit attributable to controlling shareholders, compared with the 2025 loss, are the most direct checkpoints.

  2. Around the regular shareholders' meeting in March 2027

    Dividend decisions are typically disclosed after annual closing. Because dividend levels are currently not significant, any dividend disclosure would provide a factual basis on shareholder returns.

  3. By May 15, 2027

    This is the deadline for the Q1 2027 quarterly report. It will show whether operating profit continues the trend from the KRW 439 million recorded in Q1 2026 and whether operating cash flow recovers.

  4. Ad hoc disclosures (from November 2026)

    Watch for disclosures on Optipet's overseas exports, the enzyme distributor agreement and food ingredient launches. If revenue contribution is disclosed, the shift in mix beyond feed can be tracked.

12

Overall view

Milae Bioresources is centered on feed additives and pet health supplements, and its 2025 operating loss of KRW 1.44 billion and net loss attributable to controlling shareholders of KRW 3.26 billion extended a run of losses.

In 2026, operating profit turned positive in Q1 and increased for two consecutive quarters through Q3, and controlling-shareholder net profit returned to positive in Q3.

However, Q3 2026 operating profit fell 35.7% year on year, and the last four quarters total a net loss of KRW 3.08 billion, so an earnings-based multiple is not calculated. The price-to-book ratio is below 1 times, and the debt ratio was 37.9% in 2025.

External factors such as reliance on imported raw materials, exchange rates and egg prices affect results. The next checkpoints are the operating margin and controlling-shareholder net profit in the 2026 annual business report, and the operating profit trend in the Q1 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. jobkorea.co.kr
  2. m.jobkorea.co.kr
  3. incruit.com
  4. jobkorea.co.kr
  5. kind.krx.co.kr
  6. saramin.co.kr
  7. kind.krx.co.kr
  8. kofia.or.kr
  9. asiae.co.kr
  10. m.thinkpool.com
  11. comp.wisereport.co.kr
  12. youtube.com
  13. kr.investing.com
  14. comp.fnguide.com
  15. markets.hankyung.com
  16. comp.fnguide.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis